AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23542800
Drug: Standard ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ventilation strategy (tidal volume of 9 ml/kg ideal body weight and zero-positive end-expiratory pressure)
Trial: 19874247
Drug: Antidepressants and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants and hormonal supplements
Trial: 17085763
Drug: Integrated care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated care treatment model
Trial: 17085763
Drug: Treatment initiation
RxNorm normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment initiation
Trial: 17085763
Drug: Predictors of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictors of research adherence and treatment initiation
Trial: 14727010
Drug: L‐T4 (n=31)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐T4 (n=31)
Trial: 9466067
Drug: Warfarin continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin continued (17 patients, 85%)
Trial: 9466067
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-warfarin)
Trial: 3279916
Drug: 200 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/kg phospholipid given intratracheally (treatment group)
Trial: 31487797
Drug: Kefir (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kefir (180 mL/day)
Trial: 26025412
Drug: Contraceptive pill
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive pill + flare-up GnRH‐agonist protocol (P2)
Trial: 26025412
Drug: GnRH‐antagonist protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH‐antagonist protocol (P3)
Trial: 24273972
Drug: Nitroglycerine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerine (1 mg sublingual administration)
Trial: 19484202
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of two or more drugs
Trial: 8626358
Drug: Nefazodone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (200 to 600 mg/day)
Trial: 8626358
Drug: Imipramine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (100 to 300 mg/day)
Trial: 8626358
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 to 6 capsules/day)
Trial: 1627372
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant interleukin-2 (300 micrograms/m2)
Trial: 1627372
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant interleukin-2 (300 micrograms/m2)
Trial: 1627372
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant interleukin-2
Trial: 1627372
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant interleukin-2
Trial: 31234642
Drug: Eptinezumab 10
RxNorm normalized name: EPTINEZUMAB 100 mg in 1 mL INTRAVENOUS INJECTION [Vyepti]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptinezumab 10 mg
Trial: 30345457
Drug: Crisaborole ointment
RxNorm normalized name: Crisaborole Ointment
DrugBank: Crisaborole (DB05219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crisaborole ointment
Trial: 22465890
Drug: Intravenous erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous erythropoietin (20,000 unit/24 hours) for 5 consecutive days along with intravenous methyl prednisolone (1000 mg/24 hours)
Trial: 22465890
Drug: Intravenous methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous methyl prednisolone (1000 mg/24 hours) and placebo
Trial: 20526703
Drug: CLD 100
RxNorm normalized name: CldAdo
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CLD 100 mg IM weekly for 12 months
Trial: 20526703
Drug: CLD 200
RxNorm normalized name: CldAdo
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CLD 200 mg IM every 2 weeks for 12 months
Trial: 9220520
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance therapy (Control)
Trial: 9220520
Drug: Serum ECP
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum ECP > or = 16 micrograms/L
Trial: 9220520
Drug: Serum ECP
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum ECP < 16 micrograms/L
Trial: 9220520
Drug: Serum ECP
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum ECP > or = 8 micrograms/L
Trial: 8427515
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day tiludronate for five days
Trial: 8427515
Drug: 800 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/day tiludronate for five days
Trial: 8427515
Drug: 1200 mg/day
RxNorm normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg/day tiludronate for five days
Trial: 3113413
Drug: Simple electrolyte
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple electrolyte solutions or isocaloric parenteral regimes without fat emulsion
Trial: 3113413
Drug: Dextrose or
RxNorm normalized name: Dextrose Oral Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose or amino acid solutions
Trial: 29177979
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser and topical treatment
Trial: 29177979
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment only
Trial: 16188911
Drug: 3-h intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-h intravenous infusion of glucagon-like peptide-1 (GLP-1) with a dairy breakfast
Trial: 16188911
Drug: 3-h intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-h intravenous infusion of saline with a dairy breakfast
Trial: 16188911
Drug: 3-h intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-h intravenous infusion of glucagon-like peptide-1 (GLP-1)
Trial: 16188911
Drug: 3-h intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-h intravenous infusion of saline
Trial: 12657991
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of tropisetron
Trial: 10747265
Drug: Oral piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral piroxicam 1 mg/kg/day
Trial: 10747265
Drug: Soluble aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble aspirin 100 mg/kg/day taken four-hourly
Trial: 8936562
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (25 g) administered immediately after fluoxetine
Trial: 8936562
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (25 g) administered 2 hours after fluoxetine
Trial: 8936562
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (25 g) administered 4 hours after fluoxetine
Trial: 8936562
Drug: Fluoxetine on
RxNorm normalized name: Fluoxetine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine on an empty stomach with water only
Trial: 1539484
Drug: labetalol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol 0.5 mg.kg‐1 i.v. in addition to isoflurane
Trial: 23635049
Drug: Penicillin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin (250 mg twice a day for 12 months)
Trial: 19268929
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg twice a day (group A, 15 subjects)
Trial: 16789979
Drug: Thyroxine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxine treatment for 1 year
Trial: 14510745
Drug: Gastric-retentive floating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric-retentive floating tablet administered with three different solid meals
Trial: 10868321
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT) with varying electrode placement and stimulus intensity
Trial: 10868321
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT) with right unilateral (RUL) electrode placement
Trial: 9124826
Drug: Cefodizime (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefodizime (2,000 mg as an intravenous bolus; n = 6)
Trial: 9124826
Drug: Cefpirome (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome (2,000 mg as an intravenous bolus; n = 6)
Trial: 9124826
Drug: Fleroxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin (400 mg orally; n = 6)
Trial: 9124826
Drug: Dirithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dirithromycin (250 mg orally; n = 4)
Trial: 1389343
Drug: dentin bonding
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dentin bonding agent
Trial: 3926504
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of insulin (0.67 nmol kg‐1 body weight)
Trial: 3926504
Drug: Control (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (blood taken before insulin administration)
Trial: 31424389
Drug: No psychotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No psychotropic drugs (NO)
Trial: 29275871
Drug: Rivaroxaban without
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban without aspirin
Trial: 27766505
Drug: Oral supplement
RxNorm normalized name: Healios Oral Supplement Unflavored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplement of properly balanced omega-3 and omega-6 fatty acids
Trial: 27766505
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine treatment
Trial: 27766505
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of omega-3 and omega-6 fatty acids with topical cyclosporine
Trial: 23959782
Drug: Tea with
RxNorm normalized name: MENTHOL 4.1 mg ORAL LOZENGE [SUGAR FREE GREEN TEA WITH ECHINACEA COUGH SUPPRESSANT THROAT DROPS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tea with milk (250 ml black tea plus 50 ml of full fat milk)
Trial: 8617188
Drug: Black tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black tea (300 ml)
Trial: 22294639
Drug: GO‐ON (MW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GO‐ON (MW 800‐1500 kD, 25 mg/2.5 ml)
Trial: 22294639
Drug: Hyalgan (MW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyalgan (MW 500‐730 kD, 20 mg/2 ml)
Trial: 18636279
Drug: Epidural bupivacaine/morphine/clonidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine/morphine/clonidine
Trial: 12610037
Drug: Vardenafil (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil (both doses)
Trial: 1780819
Drug: Arnica 10(‐30)
RxNorm normalized name: Arnica
DrugBank: Arnica montana flower (DB14343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arnica 10(‐30) five pills twice daily for five days, starting the day before the event.
Trial: 17519400
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg emtricitabine qd for 7 days
Trial: 17519400
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg tenofovir disoproxil fumarate qd for 7 days
Trial: 17519400
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg emtricitabine plus 300 mg tenofovir disoproxil fumarate qd for 7 days
Trial: 16236942
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg/kg before anesthesia induction and 0.5 mg/kg after 8 h; n = 10)
Trial: 10202874
Drug: Pyridostigmine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (60 mg orally twice daily from the first day of COH until the day of hCG injection)
Trial: 7750319
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss combined with sleeping on side and nasal spray
Trial: 2316014
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (6 g daily for three months)
Trial: 2316014
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 g corn oil for three months)
Trial: 6270966
Drug: Adjuvant local
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant local radiation therapy
Trial: 6270966
Drug: Cyclic treatment
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic treatment with 5‐Fluorouracil, Methotrexate and Chlorambucil
Trial: 25791613
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (2 mg/24 h on days 1 to 3, followed by 4 mg/24 h on days 4 to 6)
Trial: 25791613
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (2 mg/24 h and 4 mg/24 h)
Trial: 10586011
Drug: Systemic prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic prednisolone mixture 2 mg/kg daily for 5 days
Trial: 1536632
Drug: Control (symptomatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (symptomatic drugs only)
Trial: 1871492
Drug: Immunotherapy by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy by oral route
Trial: 31227397
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of tranexamic acid (TXA) 10 mL (100 mg/mL)
Trial: 31227397
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of tranexamic acid (TXA)
Trial: 31227397
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no TXA injections)
Trial: 27881670
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with three daily isoenergetic meals
Trial: 23624489
Drug: CB1 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB1 receptor binding in SCZ patients (SCZ-T and SCZ-F)
Trial: 23624489
Drug: CB1 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB1 receptor binding in SCZ-F patients
Trial: 19801100
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg intraoperative dexamethasone
Trial: 19801100
Drug: 0.7 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 mg/kg intraoperative dexamethasone
Trial: 12837712
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication intervention (paroxetine switched to bupropion if lack of response) (n = 88)
Trial: 12837712
Drug: Psychotherapy intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychotherapy intervention (8 weeks of manual-guided cognitive behavior therapy) (n = 90)
Trial: 10333940
Drug: Diagnosis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnosis of diabetes based on 2-h glucose load after a 75-g glucose load.
Trial: 341940
Drug: Mianserin hydrochloride
RxNorm normalized name: Mianserin hydrochloride
DrugBank: Mianserin (DB06148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin hydrochloride 20 mg
Trial: 341940
Drug: Mianserin 20
RxNorm normalized name: mianserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin 20 mg three times daily
Trial: 341940
Drug: Desmethylimipramine 25
RxNorm normalized name: Desmethylimipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desmethylimipramine 25 mg three times daily
Trial: 29175121
Drug: Elevated unmethylated
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated unmethylated insulin DNA
Trial: 29175121
Drug: Elevated methylated
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated methylated insulin DNA
Trial: 27416887
Drug: Fludrocortisone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone (50 μg oral dose)
Trial: 12271805
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy for the prevention of psychosis
Trial: 31314108
Drug: darunavir/ritonavir 800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/ritonavir 800/100 mg monotherapy
Trial: 28625256
Drug: Norepinephrine (>
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (> 1 μg/min)
Trial: 25736441
Drug: Dose change-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose change-based method for calculating individual patient time in therapeutic range (iTTR)
Trial: 19327603
Drug: Urapidil (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (12.5 mg, ic)
Trial: 10611189
Drug: Melatonin 6
RxNorm normalized name: melatonin 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 6 mg orally every day at 1700 h for 1 month
Trial: 9189814
Drug: Elastase (10800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elastase (10800 EL. U. P.O. per day) with an antiplatelet drug
Trial: 9189814
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (only antiplatelet drug)
Trial: 9189814
Drug: Elastase (10800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elastase (10800 EL. U. P.O. per day) with an antiplatelet drug (when autogenous saphenous veins were used)
Trial: 9189814
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (only antiplatelet drug, when autogenous saphenous veins were used)
Trial: 3887547
Drug: Antacid (Novaluzid;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (Novaluzid; 10 ml seven times daily, with a neutralizing capacity of 600 mmol H+)
Trial: 29651052
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine based multiple injections (MDI) therapy
Trial: 22732135
Drug: Self-monitoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring of mood, stress, and daily activities for 2 to 4 weeks.
Trial: 22732135
Drug: Attention comparison
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention comparison group (only daily activities monitored) for 2 to 4 weeks.
Trial: 20032123
Drug: Concomitant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemoradiotherapy (CT/RT) alone (arm A: two cycles of cisplatin 20 mg/m(2), days 1-4, plus 5‐fluorouracil 800 mg/m(2)/day 96 h continuous infusion during weeks 1 and 6 of radiotherapy)
Trial: 20032123
Drug: Induction docetaxel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction docetaxel, cisplatin and 5‐fluorouracil (TPF) followed by concomitant chemoradiotherapy (arm B: three cycles of TPF: docetaxel 75 mg/m(2) and cisplatin 80 mg/m(2), day 1, and 5‐fluorouracil 800 mg/m(2)/day 96 h continuous infusion, every 3 weeks)
Trial: 10834024
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamins (30,000 IU vitamin A, 1 g vitamin C, 70 mg vitamin E, 2 g calcium)
Trial: 10834024
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamins (after 6 months discontinuation)
Trial: 10834024
Drug: Placebo (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (after 6 months discontinuation)